Brighter delivers Actiste® devices and consumables to Salford Royal Hospital in the UK
Brighter AB (publ) (“Brighter” “The Company'') announces today that it has delivered the first batch of Actiste® devices and consumables to the UK’s Salford Royal Hospital.
The delivery is in preparation for the previously announced clinical research with the Northern Care Alliance NHS Foundation Trust in the City of Salford. With this high-level clinical research Brighter aims to evaluate the medical impact and disclose scientifically relevant insights about the potential benefits that Actiste® Diabetes Management as a Service can provide for the management of both type 1 and type 2 insulin-treated diabetes.
“This is a landmark day for Actiste® and a strategically important step for Brighter,” says Dragan Zdravkovic, Head of Medical Affairs at Brighter. “We are very excited to start the final preparation for the patient recruitment process, which is expected to start in March 2022.”
“User-experience projects and clinical research provide essential scientific evidence in demonstrating the potential benefits of Actiste® Diabetes Management as a Service. These kinds of insights are of high interest to the scientific community, care providers, our partners, health care insurance and of course people struggling with diabetes,” says Zdravkovic.
The positive results with Actiste® gained from the user-experience research in Sweden have also been published in the UK scientific journal “Cardiovascular Endocrinology & Metabolism” under the title “Actiste diabetes management as a service innovation – impact on everyday life – Swedish patients experience assessed by validated MedTech20 questionnaire”. Read more here.
For more information, please contact:
Investor Relations
ir@brighter.se
Certified Adviser
Brighter's Certified Adviser is Eminova Fondkommission AB,
+46 (0)8 - 684 211 10
adviser@eminova.se,www.eminova.se.
About Brighter AB (publ)
Brighter is a health-tech company from Sweden with a vision of a world where managing chronic diseases is no longer a struggle. We believe a data-centric approach is a key to providing smarter care for chronic conditions. Our daily-care solutions are designed with a vision to facilitate the flow of real-life treatment data between chronic-disease patients, their loved ones, and their care providers – aiming to improve quality of life, easing the burden on healthcare systems, and opening new opportunities for data-driven research. Brighter's quality management system is ISO-13485 certified. In 2019 the company won the Swecare Rising Stars Award. The Company's shares are listed on Nasdaq First North Growth Market/BRIG.
For more information, please visit our website at https://brighter.se/.